Boston Scientific
BSX · NYSE
$45.58+$0.53 (+1.18%)TodayMarket closed ·
Prev close $45.05
EPS: actual vs estimate
Beat the estimate in 8 of the last 8 quarters, by 4.3% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- $0.75
- Revenue estimate
- $5.11B
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | $0.8354 | $0.86 | +2.9% |
| Q1 FY26 | $0.7945 | $0.80 | +0.7% |
| Q4 FY25 | $0.7873 | $0.80 | +1.6% |
| Q3 FY25 | $0.7207 | $0.75 | +4.1% |
| Q2 FY25 | $0.7318 | $0.75 | +2.5% |
| Q1 FY25 | $0.6784 | $0.75 | +10.6% |
| Q4 FY24 | $0.6629 | $0.70 | +5.6% |
| Q3 FY24 | $0.5928 | $0.63 | +6.3% |
Earnings calls
- Wells Fargo 21st Annual Healthcare Conference
- BSX - Earnings call Q2 2026
- Bernstein 42nd Annual Strategic Decisions Conference
- BSX - Earnings call Q1 2026
- American College of Cardiology 75th Annual Scientific Session and Expo
- TD Cowen 46th Annual Health Care Conference
- BSX - Earnings call Q4 2025
- Boston Scientific Corporation, Penumbra, Inc. - M&A Call
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.